These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 8758003)

  • 1. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals.
    Luxton JC; Rowe AJ; Cridland JC; Coletart T; Wilson P; Shepherd PS
    J Gen Virol; 1996 Jul; 77 ( Pt 7)():1585-93. PubMed ID: 8758003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia.
    Shepherd PS; Rowe AJ; Cridland JC; Coletart T; Wilson P; Luxton JC
    J Gen Virol; 1996 Apr; 77 ( Pt 4)():593-602. PubMed ID: 8627247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls.
    Luxton JC; Rose RC; Coletart T; Wilson P; Shepherd PS
    J Gen Virol; 1997 Apr; 78 ( Pt 4)():917-23. PubMed ID: 9129666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of HLA-DRB1*0901-binding HPV-16 E7 helper T cell epitope.
    Okubo M; Saito M; Inoku H; Hirata R; Yanagisawa M; Takeda S; Kinoshita K; Maeda H
    J Obstet Gynaecol Res; 2004 Apr; 30(2):120-9. PubMed ID: 15009616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology.
    Tsukui T; Hildesheim A; Schiffman MH; Lucci J; Contois D; Lawler P; Rush BB; Lorincz AT; Corrigan A; Burk RD; Qu W; Marshall MA; Mann D; Carrington M; Clerici M; Shearer GM; Carbone DP; Scott DR; Houghten RA; Berzofsky JA
    Cancer Res; 1996 Sep; 56(17):3967-74. PubMed ID: 8752165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
    Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
    J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia.
    Bontkes HJ; de Gruijl TD; van den Muysenberg AJ; Verheijen RH; Stukart MJ; Meijer CJ; Scheper RJ; Stacey SN; Duggan-Keen MF; Stern PL; Man S; Borysiewicz LK; Walboomers JM
    Int J Cancer; 2000 Oct; 88(1):92-8. PubMed ID: 10962445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular biologic study on the carcinogenesis of HPV in uterine cervical cancer and related lesions--analysis of HPV types 16, 18 E6/E7 gene mRNA].
    Nagai N
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Aug; 42(8):823-33. PubMed ID: 2172419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment.
    Luxton JC; Nath R; Derias N; Herbert A; Shepherd PS
    J Gen Virol; 2003 May; 84(Pt 5):1063-1070. PubMed ID: 12692269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
    Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
    Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Stukart MJ; Doekhie FS; Remmink AJ; Helmerhorst TJ; Verheijen RH; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
    Cancer Res; 1998 Apr; 58(8):1700-6. PubMed ID: 9563486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.
    Nakagawa M; Stites DP; Farhat S; Sisler JR; Moss B; Kong F; Moscicki AB; Palefsky JM
    J Infect Dis; 1997 Apr; 175(4):927-31. PubMed ID: 9086151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the antibodies against human papillomavirus 16 E4 and E7 proteins with cervical cancer positive for human papillomavirus DNA.
    Onda T; Kanda T; Zanma S; Yasugi T; Watanabe S; Kawana T; Ueda K; Yoshikawa H; Taketani Y; Yoshiike K
    Int J Cancer; 1993 Jun; 54(4):624-8. PubMed ID: 8390409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
    Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
    Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
    Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
    Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific.
    Kadish AS; Romney SL; Ledwidge R; Tindle R; Fernando GJ; Zee SY; Van Ranst MA; Burk RD
    J Gen Virol; 1994 Sep; 75 ( Pt 9)():2277-84. PubMed ID: 8077925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
    Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
    Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.